Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512) rose nearly 5% CBT-001 international multi-center phase III study reached the main clinical end point to significantly control pterygium lesions

The Zhitong Finance App learned that Yuanda Pharmaceutical (00512) rose nearly 5%. As of press release, it had risen 4.2% to HK$4.465, with a turnover of HK$7.122 million.

According to the news, on November 5, Yuanda Pharmaceutical announced that the international multi-center phase III clinical trial of the company's innovative global ophthalmology drug CBT-001 (GPN00153) reached the main clinical end, and CBT-001 was proven to be able to change the course of pterygium disease. This means that CBT-001 is the world's first drug to show therapeutic effects on pterygium by statistically significantly improving congestion and lesion size. It is expected to fill the gaps in pterygium treatment in the future and bring new choices to patients around the world.

It is worth mentioning that Yuanda Pharmaceutical has exclusive production (including technology transfer) and commercialization rights for CBT-001 in mainland China, Hong Kong, Macau, and Taiwan. If successfully approved for marketing, CBT-001 will become the world's first product for treating pterygium. It will not only completely change the current clinical treatment pattern of pterygium, bring new non-surgical treatment options to hundreds of millions of patients, but also build the company's differentiated competitive advantage in the field of anti-inflammatory and proliferative diseases in ophthalmology.